Byoung Yong Shim

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Sehhoon Park, Tae Min Kim, Ji‐Youn Han et al. · Journal of Clinical Oncology · 2023 · 164 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Byoung Chul Cho, Ji‐Youn Han, Sang‐We Kim et al. · Journal of Thoracic Oncology · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +13

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen et al. · Cancer · 2021 · 70 citations · Full text

Medicine, Oncology, Pharmacology +14

Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size

Jong Hoon Lee, Sung Hwan Kim, Young Jin Suh et al. · Cancer Research and Treatment · 2010 · 63 citations · Full text

Medicine, Oncology, Surgery +17